Impurity testing of ranitidine products: US FDA update

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1779卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71265-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1 / 1

相关论文

共 50 条

[1] Impurity Testing of Ranitidine Products: US FDA Update
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 70 - 70
[2] US FDA recommends LC-HRMS for testing ranitidine products
Reactions Weekly, 2019, 1774 (1) : 6 - 6
[3] FDA requests market withdrawal of all ranitidine products
Reactions Weekly, 2020, 1799 (1) : 4 - 4
[4] FDA recalls ranitidine medicines over potential cancer causing impurity
Mahase, Elisabeth
BMJ-BRITISH MEDICAL JOURNAL, 2019, 367 : l5832
[5] Update on the Office of Drug Safety at the US FDA
Reactions Weekly, 2004, 1015 (1) : 3 - 4
[6] FDA Regulation of Tobacco Products in the US
Zeller, Mitch
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S98 - S98
[7] US FDA update on nitrosamine impurities investigation
Reactions Weekly, 2019, 1739 (1) : 2 - 2
[8] US Senate limits FDA testing
Kohl, M
JOURNAL OF REFRACTIVE SURGERY, 1997, 13 (07): : 612 - 612
[9] Impurity Testing of Biologic Drug Products
Siew, Adeline
BIOPHARM INTERNATIONAL, 2018, 31 (02) : 14 - 19
[10] Nitrosamine impurity in ranitidine
Reactions Weekly, 2019, 1772 (1) : 3 - 3

← 1 2 3 4 5 →